再生元制药
✦ 量化合理价值 计算方式说明
- 基于该股自身过去5年平均市盈率乘以滚动每股收益，推算出的合理价值区间为499.38-1,004.85。
- 当前价格比按平均倍数计算的合理价值（752.12）高5.1%。
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 再生元制药 (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
| Revolution Medicines (RVMD) | 38.14B | -20.06 | 14.63 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算6.9%。
合理价值
Regeneron Pharmaceuticals Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% discount to our quantitative fair value estimate of $736.52 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
作者：Quantitative Equity Report
报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
再生元制药 讨论区 0 条评论